Drug news
Nice rejectes Esbriet (InterMune) as a treatment for Pulmonary Fibrosis
The National Institute for Health and Clinical Excellence (NICE) has rejected the use of Esbriet(pirfenidone), from InterMune, on the National Health Service to treat patients with idiopathic Pulmonary Fibrosis as it finds the drug is not cost effective.